Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
347 1 |
Ultima descărcare din IBN: 2023-03-23 18:20 |
Căutarea după subiecte similare conform CZU |
616.65-006.55-07-08 (1) |
Patologia sistemului urogenital. Boli urinare şi sexuale (genitale) (368) |
SM ISO690:2012 PLEŞACOV, Alexei, GHICAVÎI, Vitalie. Thulium: Yag laser vapoenucleation of the prostate vs. Standard transurethral resection in benign prostatic hyperplasia treatment. In: Archives of the Balkan Medical Union, 2021, nr. 1(56), pp. 58-65. ISSN 1584-9244. DOI: https://doi.org/10.31688/ABMU.2021.56.1.07 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Archives of the Balkan Medical Union | |||||
Numărul 1(56) / 2021 / ISSN 1584-9244 | |||||
|
|||||
DOI: https://doi.org/10.31688/ABMU.2021.56.1.07 | |||||
CZU: 616.65-006.55-07-08 | |||||
Pag. 58-65 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Introduction. Thulium:YAG laser has been increasingly used in retrograde transurethral enucleation of the prostate as a new advanced surgical treatment in benign prostatic hyperplasia (BPH). The implementation of Thulium:YAG laser prostatic vapoenucleation (ThuVEP) will allow patients with large BPH, who have traditionally been treated via open adenomectomy or monopolar transurethral resection, to undergo minimally invasive endoscopic treatment by using laser energy. The objective of the study was to provide a comparative assessment of ThuVEP vs. standard transurethral resection (TURP) in the treatment of benign prostatic hyperplasia. Material and methods. The study was conducted on 81 patients with BPH, regarding the appropriate surgical treatment, including ThuVEP (40 patients) and TURP (41 patients), from May to December 2018. All patients were assessed before surgery and 3, 6 and 12 months after surgery. The obtained data were compared retrospectively. Results. ThuVEP has proven its long-expected surgical efficacy. The main urodynamic and ultrasonographic indices at 12 months postoperatively showed no statistically significant difference. Moreover, the incidence rate of surgical complications was lower in the ThuVEP group. Patients from the ThuVEP group did not require further blood transfusions. Conclusions. ThuVEP exhibited major efficacy and maximum efficiency in the treatment of BPH in our study. Thulium:YAG laser used in the surgical treatment of BPH is considered superior compared to the classic TURP endourological technique, as well as promising for clinical practice. Further long-term patients' follow-up is necessary to assess the durability of the intervention. |
|||||
Cuvinte-cheie laser, prostate, Thulium:yag vapoenucleation |
|||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <identifier identifierType='DOI'>10.31688/ABMU.2021.56.1.07</identifier> <creators> <creator> <creatorName>Pleşacov, A.</creatorName> <affiliation>IMSP Spitalul Clinic Republican „Timofei Moșneaga”, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Ghicavîi, V.V.</creatorName> <affiliation>IMSP Spitalul Clinic Republican „Timofei Moșneaga”, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='en'>Thulium: Yag laser vapoenucleation of the prostate vs. Standard transurethral resection in benign prostatic hyperplasia treatment</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2021</publicationYear> <relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1584-9244</relatedIdentifier> <subjects> <subject>laser</subject> <subject>prostate</subject> <subject>Thulium:yag vapoenucleation</subject> <subject schemeURI='http://udcdata.info/' subjectScheme='UDC'>616.65-006.55-07-08</subject> </subjects> <dates> <date dateType='Issued'>2021-03-18</date> </dates> <resourceType resourceTypeGeneral='Text'>Journal article</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>Introduction. Thulium:YAG laser has been increasingly used in retrograde transurethral enucleation of the prostate as a new advanced surgical treatment in benign prostatic hyperplasia (BPH). The implementation of Thulium:YAG laser prostatic vapoenucleation (ThuVEP) will allow patients with large BPH, who have traditionally been treated via open adenomectomy or monopolar transurethral resection, to undergo minimally invasive endoscopic treatment by using laser energy. The objective of the study was to provide a comparative assessment of ThuVEP vs. standard transurethral resection (TURP) in the treatment of benign prostatic hyperplasia. Material and methods. The study was conducted on 81 patients with BPH, regarding the appropriate surgical treatment, including ThuVEP (40 patients) and TURP (41 patients), from May to December 2018. All patients were assessed before surgery and 3, 6 and 12 months after surgery. The obtained data were compared retrospectively. Results. ThuVEP has proven its long-expected surgical efficacy. The main urodynamic and ultrasonographic indices at 12 months postoperatively showed no statistically significant difference. Moreover, the incidence rate of surgical complications was lower in the ThuVEP group. Patients from the ThuVEP group did not require further blood transfusions. Conclusions. ThuVEP exhibited major efficacy and maximum efficiency in the treatment of BPH in our study. Thulium:YAG laser used in the surgical treatment of BPH is considered superior compared to the classic TURP endourological technique, as well as promising for clinical practice. Further long-term patients' follow-up is necessary to assess the durability of the intervention. </p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>